Dendreon Appoints Lindsay Rocco to Lead Corporate Communications
BRIDGEWATER, N.J.-- Dendreon Corporation (NASDAQ: DNDN) today announced the appointment of Lindsay Rocco as executive vice president, corporate communications and member of the executive committee, effective immediately. In this role, Ms. Rocco will be responsible for all communications functions of the Company and will report directly to John H. Johnson, chairman, president and chief executive officer of Dendreon.
Ms. Rocco has extensive healthcare communications experience with large pharmaceutical companies as well as specialized public relations agencies. Most recently, she was senior vice president and a member of the leadership team at Rx Mosaic Health, a specialty healthcare public relations agency within the Omnicom Group. She helped to build and grow Rx Mosaic Health since its establishment six years ago, and served as a senior communications strategist for biotechnology and pharmaceutical clients within competitive and challenging therapeutic categories, including oncology, rheumatology and neurology.
"We are pleased to welcome Lindsay to Dendreon," said John H. Johnson, chairman, president and chief executive officer of Dendreon. "Lindsay is a seasoned communicator with a deep understanding of the oncology space and a true passion for Dendreon's mission to help advanced prostate cancer patients lead longer and better lives. Lindsay's energy and expertise in healthcare communications makes her an ideal addition to our leadership team."
Ms. Rocco added, "I am honored to join Dendreon at such an important time for the Company. I look forward to being a member of the executive committee and working together with the entire organization to help transform Dendreon from a pioneer to a leader in immunotherapy."
Prior to joining Rx Mosaic Health, Ms. Rocco served as a director, public affairs at Roche-Genentech. Throughout her career, Ms. Rocco has also held senior-level positions with several healthcare public relations agencies within global holding companies, including the Omnicom Group and Publicis, and with MCS Healthcare Public Relations, an independent agency.
Ms. Rocco holds a Bachelor of Business Administration in Marketing from the Joseph A. Sellinger School of Business Administration and Management at Loyola University in Maryland. She currently serves on the Board of Governors for the New York Chapter of the Arthritis Foundation.
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.
Dendreon Corporation
Investor Relations
Nicole Soley, 206-455-2220
[email protected]
or
Joele Frank, Wilkinson Brimmer Katcher
Media Relations
Andrew Brimmer, 212-355-4449
[email protected]
Source: Dendreon Corporation
News Provided by Acquire Media